Study suggests combo itch therapy may help some refractory dogs

A new retrospective study in Veterinary Dermatology suggests that combining oclacitinib and lokivetmab may help some dogs with allergic dermatitis when either drug alone hasn’t provided adequate itch control. In the 44-dog case series, 61.4% of dogs were reported to achieve adequate pruritus control after switching to combination therapy following monotherapy failure. The study adds to a small but growing body of evidence around how clinicians manage difficult canine atopic and allergic dermatitis cases when standard single-agent approaches fall short. (mendeley.com)

Why it matters: For veterinary teams, the finding is less about declaring a new standard of care and more about expanding the conversation around refractory itch management. Oclacitinib is labeled in the U.S. for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age, while lokivetmab is indicated for allergic dermatitis and atopic dermatitis, with repeat dosing every 4 to 8 weeks as needed. Importantly, Cytopoint’s package insert says a wide variety of concomitant medications, including oclacitinib, were safely used in field safety work, while Apoquel labeling says its use has not been evaluated in combination with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents. That makes this study clinically interesting, but still best interpreted as hypothesis-generating rather than practice-changing on its own. (dt2n0xjvnpvnu.cloudfront.net)

What to watch: Prospective, controlled studies will be needed to clarify which dogs benefit most, how long combination therapy should be continued, and what safety signals emerge with broader use. (mendeley.com)